Centessa Pharmaceuticals (CNTA) Equity Average (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Equity Average data on file, last reported at $507.1 million in Q1 2026.

• Equity Average for Q1 2026 came in at $507.1 million, up 28.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $507.1 million (up 28.74% YoY), and the FY2025 annual result was $464.2 million, up 45.57% from the prior year.
• Equity Average rose to $507.1 million in Q1 2026 per CNTA's latest filing, from $414.2 million in the prior quarter.
• Over five years, Equity Average peaked at $507.1 million in Q1 2026 and troughed at $225.7 million in Q1 2024.
• A 5-year average of $360.4 million and a median of $365.6 million in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2023: Equity Average surged 279.26% in 2022, then slumped 36.69% in 2023.
• A 5-year view of Equity Average shows it stood at $354.5 million in 2022, then sank by 30.1% to $247.8 million in 2023, then jumped by 81.72% to $450.3 million in 2024, then fell by 8.02% to $414.2 million in 2025, then gained by 22.42% to $507.1 million in 2026.
• Business Quant data shows CNTA's Equity Average at $507.1 million in Q1 2026, $414.2 million in Q4 2025, and $323.2 million in Q3 2025.